10% of People May Be Genetically Wired to Respond Differently to GLP-1s

Your DNA May Predict How Well GLP-1 Medications Work for You

A study of nearly 28,000 GLP-1 users, conducted by the 23andMe Research Institute and published in Nature in April 2026, found that a specific mutation in the GLP1R gene — the gene encoding the protein that GLP-1 drugs target — was modestly but significantly associated with greater weight loss. In other words, some people are genetically primed to respond better to these medications than others.

Separately, scientists identified genetic variants carried by roughly 10% of the population that appear to make people less responsive to GLP-1 drugs used to treat type 2 diabetes. While the research is early, the implications are significant: the era of one-size-fits-all GLP-1 prescribing may be ending.

What This Research Actually Found

The 23andMe study was among the largest pharmacogenomic analyses of GLP-1 medications ever conducted. Participants who reported taking GLP-1 weight-loss drugs were genotyped, and researchers looked for correlations between genetic variants and self-reported weight loss outcomes.

The key finding: a variant in the GLP1R gene was associated with greater weight loss. The effect was modest — genetics alone did not determine whether someone lost 5% or 25% of their body weight — but it was statistically significant and biologically plausible. The GLP1R gene encodes the very receptor that semaglutide and tirzepatide bind to. Variations in that receptor's structure could logically affect how well the drugs work.

Why Some People Do Not Respond — And What to Do About It

Clinical experience has always shown that GLP-1 response varies widely. Some patients lose 20% or more of their body weight; others lose 5% or less. Until now, clinicians had few tools to predict who would fall where. The emerging framework for understanding non-response includes several factors:

• Genetics. The 23andMe findings suggest receptor-level variation plays a role, but this is just one piece of the puzzle.
• The "hungry brain" vs. "hungry gut" distinction. Obesity researchers increasingly distinguish between patients whose overeating is driven primarily by brain reward pathways versus those with metabolic or hormonal gut dysfunction. GLP-1s may work differently across these phenotypes.
• Dose adequacy. Many patients labeled as "non-responders" have never reached the full therapeutic dose. Titration takes months, and some patients stop escalating at the first sign of side effects.
• Medication class mismatch. A patient who does not respond well to semaglutide (GLP-1 only) may respond significantly better to tirzepatide (GLP-1 + GIP dual agonist). Switching classes is a legitimate clinical strategy.

Questions to Ask Your Doctor If You Feel Like a Non-Responder

If you have been on a GLP-1 medication for three or more months and are not seeing meaningful results, here is how to approach the conversation:

• Am I at the therapeutic dose? If you are still on a titration dose, you have not yet given the medication a full trial.
• Should we try a different medication? Switching from semaglutide to tirzepatide (or vice versa) is a well-established clinical approach for partial responders.
• Could the new higher dose help? Wegovy HD 7.2mg was specifically approved for patients who have tolerated 2.4mg but need additional weight reduction.
• Are there other factors? Thyroid dysfunction, cortisol abnormalities, medication interactions (such as certain antidepressants), and sleep disorders can all blunt GLP-1 response.
• Is genetic testing useful yet? Honestly, not in clinical practice — not yet. But this is worth following as the science matures.